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Abstract
Good clinical practice (GCP) is a series of systematically developed ethical and quality 
standard of designing, registering, running, recording, and reporting of the clinical trials. 
Good clinical practice is very important regarding the trials usually performed on the 
vulnerable populations especially children and adolescents. The sensitivity of the issue 
is even higher in the children with psychiatric disorders. Usually, these children have 
little legal protection. Hence, the safety of interventions and the ethical considerations are 
among the most important issues in this field. The purpose of this chapter is to deal with 
above problems and globally applicable standards for the conduct of clinical trials on 
the under legal age subjects especially those with psychiatric disorders. Selection of trial 
subjects, ethical principles, regulatory requirements, protection of trial subjects, monitor-
ing (compliance with the protocol), responsibilities of the investigator, and other require-
ments to perform a clinically and ethically sound clinical trial in children and adolescents 
will be discussed in this chapter.
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1. Introduction
While new medical products (drugs and vaccines) are being developed and asking for regis-
tration, their efficacy and safety should be assessed in a well-designed clinical trial, ultimately 
on human beings [1]. This process is costly, and ethical considerations are controversial. The 
history of developing of good clinical practice (GCP) goes back to the end of World War 2 
following the Nuremberg trials on war victims. In Nuremberg Nazi, physicians were accused 
for performing inhumane trials on human beings in the name of medical research. After the 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
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war, two American doctors who were present in Nuremberg invented a set of research ethics 
principles including 10 points which are in compliance to the human rights. These principles 
are known as Nuremberg Codes [2, 3].
Later in 1964, the elected medical representatives came from all over the world, attended 
the 18th General Assembly of the World Medical Association in Helsinki. They decided to 
improve the points asserted in the Nuremberg Code and create a more formal statement of 
ethical principles. Its attitude was to provide detailed directions for medical science research-
ers to conduct the trials on human subjects with scientifically sound methods and in accor-
dance with basic ethical principles. This statement is known as the “Declaration of Helsinki,” 
and until now, several revisions have been released [4].
This history formed the basis for developing good clinical practice.
2. Good clinical practice definition
Good clinical practice is an internationally accepted scientific and ethical standard for the 
design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of 
clinical trials on human subjects which provides assurance that the reported results are cred-
ible and accurate; the rights, integrity, and confidentiality of trial subjects are protected [3].
The good clinical practice is a quality assurance system for the conduct of clinical trials. It is a 
legal requirement accepted by health systems in many countries. Hence, a new product will not 
be licensed by regulatory authorities if the rules of good clinical practice are not followed [5].
3. Selection of trial subjects
Patient selection for any clinical trial is a very critical point. When choosing the inclusion cri-
teria, the researcher should think that what factors are important to the research question and 
include the main characteristics of target population. The researcher should be careful that 
excessive exclusion may degeneralize the study. The caseness of pediatric subjects should be 
confirmed by a pediatrician. When working on pediatric psychiatric patients, the sensitivity 
is much more, the eligibility of subjects must be clearly defined in the inclusion and exclusion 
criteria. Furthermore, the diagnosis must be confirmed by a child and adolescent psychiatrist 
based on the latest version of diagnostic and statistical manual of mental disorders (DSM). 
In psychiatry trials, documentation and history of the diagnosis are usually required [6, 7].
4. Protection of trial subjects
Childhood period comes with rapid growth and development and ends with puberty. 
Unfortunately, sometimes it is accompanied by harsh diseases like infection diseases, aller-
gies, cancers, and psychiatric disorders. So, many advanced vaccines and medicines are 
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needed to be developed for children and adolescents. Furthermore, some supplements are 
targeted for this group of population [8–10]. Hence, performing clinical trials on children and 
adolescents is a critical mission sometimes inevitable. Children are vulnerable population in 
medical research; hence, inclusion of children in clinical trials always is a matter of great con-
cern for parents, researchers, and ethic committees. Children and adolescents who will attend 
in the clinical trials should be selected carefully by a qualified physician. The physician should 
be qualified by sufficient education, training, and experience and should be in charge for opti-
mum health of the participants. All diagnosis should be supported by the latest clinical guide-
lines [11]. Furthermore, inclusion and exclusion criteria should be carefully set on the basis 
of study objectives and previous studies. The processes of medical care and every decisions 
made here should be based on evidence and guarantee the maximum safety of the patients 
in a way that the rights and well-being of the children would be protected. Blood sampling in 
children is not ethical if the benefits of the study do not exceed the harms for children. When a 
specific group of children directly benefit from blood sampling or blood sampling is necessary 
for diagnosis, the documents should be presented to the institutional ethics committee and 
benefits should be described to the parents or legal guardians. The subjects or his/her parent 
or legal guardian should be adequately informed about the processes of research, the rights 
and responsibilities. The aims and methods of the research should brightly be described to 
them. Furthermore, the subjects and their legal guardian must be aware of anticipated benefits 
and potential hazards of the intervention. Then, informed consent must be signed by the par-
ents or legal guardian of the subjects below the legal age. Moreover, the subjects should ascent 
to participate. Then, after obtaining sufficient ethical approvals and consent forms, blood sam-
pling could be gathered by a trained client under the guidance of existing guidelines [12, 
13]. In clinical trials on pediatric psychiatry, a team-based approach involving the laboratory 
physician would help the quality assurance of examination, diagnosis, and reporting, as well 
as patient safety [14, 15].
5. Safety reporting
In trials with the main objective of efficacy assessment, the safety assessment is usually the 
secondary objective. One of the responsibilities of the researcher is to carefully monitor the 
adverse effects and record immediately when a participant experiences any side effect [16]. 
Then, the investigator should report it in a suitable way. Furthermore, in respecting the pri-
vacy, the researchers should guarantee the confidentiality of records that could identify the 
subject. Another duty of the researcher is to provide best possible care available and follow 
until complete disappearance of adverse effect. Sometimes, it is necessary to stop the trial to 
protect one or more subjects. Sometimes, the subjects or the legal guardian themselves decide 
to stop medication. In pediatric psychiatry, loss to follow-ups happens due to adverse effects 
of the intervention, stigma, and lack of parent’s knowledge about medicinal psychotherapy 
[17]. So, the researcher should conduct a thorough investigation and find the exact reason of 
each loss to follow-up and report it. Usually, identifying the barriers and reducing them would 
be helpful. Educating the parents and legal guardians to help reduce the stigma of referring to 
psychiatrist and fear of tacking psychiatry medications may support the children health [18].
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6. Develop informed consent form
Consenting is the process by which participant voluntary confirms his/her willingness to par-
ticipate in the trial. The medical researchers should be careful and pay special attention when 
obtaining consent from vulnerable subjects, including children, the elderly, and psychiatric 
patients. Subjects with low perception may feel unable to make use of their right to judge 
the profits or hazards of the intervention and decide whether to consent or not. Child and 
adolescent psychiatrists should be careful about the decisional capacities of children and the 
role of the parents in medical decision making. Hence, obtaining informed consent form from 
the legal guardian of the subjects under legal age and the patients with severe psychiatric 
disorder is crucial. In addition, obtaining oral ascents from the subjects with low perception 
or children who will participate in the medical research is essential. Full procedures, rights 
and responsibilities, potential hazards, and benefits should be described to each participant 
and the legal guardian. Then, informed consent must be dated and signed by the legal guard-
ian before the subject participates into the trial. Then, a copy of informed consent form and 
related information should be delivered to the parents or guardian. The original informed 
consent must be kept in the investigator’s file [19].
7. Ethical approval
The researcher should submit the sponsor-provided protocol document to the Institutional 
Review Board (IRB) or Research Ethics Board (REB) for approval before recruiting any case 
into the trial. The investigator should also submit consent forms and assessment tools, includ-
ing questionnaires. During specific intervals, the researcher must report the progress of the 
trial and request re-approval of the research by the IRB/REB. The IRB/REB will ask for a sum-
mary of trial progress [20]. The responsibility of the ethics committee is to guarantee the pro-
tection of the rights and well-being of human subjects enrolling into clinical trials. The ethics 
board decisions are in line with the latest revision of the declaration of Helsinki and local 
pertinent regulations [21].
8. Quality of data
Every research study needs to have a written protocol which includes the plan of the study 
as detailed as possible. The design and method of the trial should be well-thought-out, and 
the protocol must be well-written and approved by a faculty council. Protocol includes the 
trial information in detail and should consist of the trial title, the name of the main investiga-
tor, supervisor/s and sponsor/s, literature review, materials and methods, characteristics of 
intervention, dosage, duration, randomization, blinding, allocation concealment, inclusion 
criteria, exclusion criteria, project schedule (Gantt chart), and budget of the project [22].
In trials performing on children and adolescents, the investigators should be trained and 
interested in the scientific aspect and ensure that the study meets the needs of patient’s health. 
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The researchers must also review up-to-date information, ensure the confidentiality of the 
data, and provide confidentiality agreement to sponsor. Furthermore, proper facilities, loca-
tion, equipment, laboratory, product storage, and archive must be provided prior to study 
initiation [22, 23].
9. Resources
One of the requirements of good clinical practice is that the researcher has adequate access to 
resources to carry out a sound clinical trial. Resources include not only sufficient budget and 
materials, but also the ability to recruit adequate numbers of research subjects. Furthermore, 
the research team members must have adequate information about their specific roles, and 
they should have adequate time to deal with subjects and conduct the trial. In trials being con-
ducted in children and adolescents, at least one of the team members should be specialized or 
trained previously to deal with the subject on this age span [24].
10. Randomization
Single-arm trials with historical controls for comparison may be biased by differences in sub-
ject characteristics (age, sex, prior therapy, phase of disorder, and supplemental care). Still, 
when matched controls can be selected, unknown confounding factors may be haphazardly 
distributed between two groups.
Designing a two-arm trial with distributing the subjects between two groups using ran-
domization can help to minimize potential bias caused by unknown confounding factors. 
However, a placebo-controlled trial may be ethically defensible when the use of placebo 
would not add any risk or serious harm to the subjects. Sometimes, crossover design is more 
ethical and adheres to the principle of good clinical practice. In crossover studies, the subjects 
are randomly allocated to the treatment or control groups, after the first phase ends, the sub-
jects will change the groups. In this design, all subjects receive all treatments. Of course, the 
priority of treatments should not harm the subjects.
When an uneven distributed factor between groups recognized, then controlling by statis-
tics method at the analyses level may be considered. One strategy is to stratify the variable 
and discuss the results at different levels of the variable. A better solution is stratification 
process at the time of randomization using the permuted blocked randomize allocation. In 
this method, randomization will be performed using different age and sex blocks. Hence, the 
subjects will distribute evenly between treatment arms.
In a randomized clinical trial to control for the placebo effect and minimize the study bias, 
the subjects and researchers should be blinded using placebo, coding, and allocation conceal-
ment. In the case of a blinded trial, the protocol must declare who and in what conditions is 
allowed to break the codes (for example, the supervisor and in emergencies). Breaking the 
codes must be justified and must be reported [21].
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11. Reports
Moving in accordance with protocol allows its accurate reporting, interpretation, monitor-
ing, and verification of the trial. Furthermore, it assures the quality of every aspects of the 
trial. The data obtained from the trial must be handled, analyzed, synthesized, and reported 
in a sound approach. In addition, the sponsor or the research institute should be able to 
carry out on-site inspections of the validity of reported results. Hence, brilliant documenta-
tions and reporting are very important as well as the monitoring processes. For this pur-
pose, the research institute should have easy access to all patient files and raw data during 
the trial [21].
12. Monitoring
Monitoring is an important part of good clinical practice. Monitoring is the process of audit-
ing the trial based on compliance to the approved protocol, ethics, and regulation in a way 
that guarantee the optimum health and rights of the subjects, as well as timely submission 
of high-quality data. The objectives of monitoring are to prevent, detect, and correct careless 
errors, neglect, fraud/misconduct, and violations. Monitoring will guarantee the quality of 
medical care, quality of data, quality of trial, and quality of product. The monitor is a person 
who has been chosen by the sponsor or research institute for the monitoring and reporting of 
progress of the trial and for the confirmation of data. The monitor should have enough medi-
cal, scientific, and/or pharmaceutical qualifications, and clinical trial experience [21].
12.1. Monitor’s responsibilities
Monitor’s responsibilities are listed below:
• To act as a soother between the sponsor and the investigator
The inspector is chosen by sponsor and is responsible for corresponding between sponsor and 
investigator.
• To help the investigators on all aspects
Helping investigators in providing supplies and solving problems is among the responsibilities of the 
inspector.
• To help protection of study subjects
Confirming obtain of informed consent for all subjects prior to their participation in the trial is one of 
the monitors responsibilities.
• To verify adequacy of trial resources
Monitor check for adequacy investigators, staff, and facilities before and throughout the study period.
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• To verify supply, control, storage, and disposition of investigational product/s
Turning back additional materials after the trial is finished is one of the inspector’s duties.
• To verify adherence to the approved protocol/amendments
Adherence to the approved protocol ensures that data are correctly gathered and reported. Any changes 
to the protocol should be documented and reported.
• To verify adherence to good clinical practice and standard operating procedures
Standard operating procedure (SOP) is a standard comprehensive framework for administration of 
clinical trials.
• To monitor recruitment rate, safety evaluation, and compliant observations
Validity and quality of data gathered and safety of patients are monitored by the inspector during the 
trial.
• To check the accuracy and completeness of all trial data and case report forms
Case report form is a paper-based or computer-based sheet that is used to record and gather the data 
on each trial subject during the trial, as defined by the protocol. The documentation should allow easy 
access for verification, audit, and inspection.
• To discuss study plan and problems with main investigator and staff
Monitors are trained in clinical trial and medical research and may collaborate to improve the quality of 
trial. They may also verify that trial documents are complete and up-to-date [25].
13. Monitoring visits
13.1. Pretrial monitoring visit
During prestudy visit, the monitor ensures feasibility of trial in the center and interest of the 
investigator. Also he/she makes sure that the investigator understands the required “trial pro-
cedures” and sufficient site staff, proper facilities, location, equipment, laboratory, product 
storage, and archive exist to support the study.
The inspector may discuss with investigator(s) about
• The protocol in detail
• Consent form
• Assenting children (if present)
• Case report form and documentation of findings including adverse effects, standard oper-
ating procedures
Good Clinical Practice in Children and Adolescents
http://dx.doi.org/10.5772/intechopen.70191
35
The audit may clarify any issues that remain uncertain, regulatory requirement and ful-
fills the sponsor expectations. He/she may document any changes in the protocol to elimi-
nate practical defects.
13.2. Trial initiation visit
Deliver study material, documents, and products, and make sure the investigational team 
understands the protocol and good clinical practice requirements.
The responsibilities of the inspector in trial initiation visit are listed below:
• Revise team training
• Ensure understanding of protocol
• Ensure understanding of case report form
• Ensure ethical requirements
• Ensure safety reporting procedure
Discuss in detail:
• Enrollment and exclusion criteria
• Endpoints
• Patients safety
• Criteria for grading adverse effects
• Handling of patient samples
• Handling of test product
• Standard operating procedures
13.3. Monitoring visit
In approach to help the investigational team in solving problems, the trained audits would make 
sure that the study is conducted in accordance with the requirements of the protocol and good 
clinical practice principles. Also they make sure that investigators are available during the visits.
Discuss:
• Problems
• Modifications
• Obtaining informed consent from legal guardian
• Obtaining assent from the children and adolescents (process by which patient/subject vol-
untarily confirms his/her willingness to participate)
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• Protocol compliance: strictly follow protocol procedures, alteration
• Sponsor approval
13.4. Close-out visit
Make sure the investigator file is archived properly and collects back all unused materials, 
documents, or products.
14. Responsibilities of the investigators after approvals
• Sign the final copy of protocol
The main investigator should sign and hereby accept the responsibility of trial.
• Submit the requested document
The main investigator should provide the requested form including budget, Gantt chart, and consent 
forms to the sponsor, the research institute and ethics committee.
• Registering the protocol of the trial in one of the clinical trial registries
Now most high-quality journals necessitate researchers to submit their work in one of clinical trial 
registries before patient’s enrollment into the trial and provide its code at the time of submission to the 
journal. He/she must also agree with publication policy of journal and publisher.
• Work according to the protocol and good clinical practice guidelines
The investigator must ensure that he/she acts in accordance with the sponsor-approved protocol and 
globally accepted standard of GCP.
• Collaborate with monitor
The investigator should collaborate in on-site inspections and in corresponding.
15. Responsibilities of the investigators during study
• Adherence to the protocol and good clinical practice principles
The investigator should adhere to the inclusion and exclusion criteria mentioned in the approved pro-
tocol. He/she has overall responsibility for ensuring the accuracy and completeness of data gathered.
• Adhering to administrative and regulatory requirements
Local regulations and administrative requirements should also be respected by the investigators.
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• Compliance with ethics
Give adequate information to the subjects and legal guardians about study procedure, harms, and ben-
efits of the intervention. Also, give adequate information to the subjects and legal guardians about 
responsibility and rights of each side. Then, obtaining freely signed informed consent form from legal 
guardian.
• Obtaining oral assent from the children and adolescents
The researcher should also spend sufficient time for participants and allow participants themselves to 
decide.
• Unbiased selection/randomization, blinding, and allocation concealment
The investigator should ensure that the subjects are correctly diagnosed and reduce the known kinds of 
biases including random bias and selection bias with adhering to clinically sound diagnosis, randomiza-
tion, blinding, and allocation concealment. These processes are discussed before.
• Be sure that dosage and instruction for use are correct
The main objective of performing a clinical trial is usually assessing the effectiveness of a product at a 
specific dose. But, the phase II clinical trials are dominantly aim at the determination of appropriate or 
safe dose ranges. Hence, determining appropriate dose and timing of product intake based on previous 
studies and literature is very important.
• Correspondence
The main investigator is responsible to correspond with the sponsor, ethics committee, and research 
institute.
• Monitoring and follow-up potential side effects
Adverse effects must be reported and monitored until its removal.
• Trial data documentation
The researcher must make sure that the participant’s identification, trial observations, findings, and 
also side effects are recorded correctly and completely in a paper-based or computer-based case report 
form (CRF). Furthermore, the investigator should fill and maintain investigator’s file.
• Laboratory quality assurance/quality control (normal lab values)
Laboratory values within or outside the normal reference ranges, if possible together with the specificity 
and sensitivity of the methods used, should always be recorded on the CRF or be attached to it.
• Secured storage and limited access to data
Suitable place for archiving and confidentiality of the data should be guaranteed by the investigator.
• Preparing the final report
The project should be based on the Gantt chart and the sponsor-approved budget. Then, the final report of 
the trial should be prepared as defined in the protocol. The report should be signed by the sponsor, moni-
tor, and investigator(s) as well as the responsible statistician, in accordance with the relevant regulations.
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16. Conclusion
Clinical trial in children and adolescents as a vulnerable population is a great concern to 
the legal guardians, medical investigators, and ethics committees. These trials must be 
planned, set up, conducted, documented, and reported in a great standard named good clini-
cal practice. The data should be collected, synthesized, and documented with accuracy and 
consistency. Furthermore, researches involving humans especially those with low percep-
tion including psychiatric patients and children, and adolescents should be scientifically 
sound and conducted in accordance with high ethical standards. Obtaining written freely 
signed informed consent form from parents or legal guardians is mandatory in clinical trials 
performing on children and adolescents. Additionally, obtaining oral assent from the sub-
ject itself is essential too. Institutional ethics committees are responsible for approving the 
trial methodology and safety in a way that ensure protecting of patient’s rights and health. 
Meanwhile, monitoring would help to guarantee the maximum quality of data and well-
being of subjects. Monitoring the clinical trial is the process of auditing trials based on the 
sponsor-approved protocol and the standard of good clinical practice. In all, the concept of 
good clinical practice in children and adolescents necessitates medical researchers a bind-
ing statement: “Performing the trial with best possible standards and optimum health of my 
patient will be my first consideration.”
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